1532533-75-7

1532533-75-7 structure

Name: TGR-1202 Sulfate
Chemical Name: TGR-1202 Sulfate
CAS Number: 1532533-75-7
Molecular Formula: C₃₁H₂₆F₃N₅O₇S
Molecular Weight: 669.62800
Catalog: Signaling Pathways Cell Cycle/DNA Damage Casein Kinase
Create Date: 2016-06-30 09:46:36
Modify Date: 2024-01-08 17:10:20
Umbralisib sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach[1][2][3][4].

Name	TGR-1202 Sulfate
Synonyms	(S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one sulfate

Description	Umbralisib sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach[1][2][3][4].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> PI3K/Akt/mTOR >> PI3K Signaling Pathways >> Cell Cycle/DNA Damage >> Casein Kinase Signaling Pathways >> Stem Cell/Wnt >> Casein Kinase
Target	PI3Kδ:6.2 (Kd) CK1ϵ:180 (Kd) PI3Kγ:1400 (Kd) PI3Kα:>10000 (Kd) PI3Kβ:>10000 (Kd)
In Vitro	Umbralisib sulfatecauses a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM[3]. In human lymphoma and leukemia cell lines, Umbralisib sulfate (10 nM-100 μM) inhibits phosphorylated AKT at Ser473 in a concentration-dependent manner[4]. Umbralisib sulfate (15-50 μM) potently represses the expression of c-Myc in the DLBCL cell line LY7, and is uniquely characterized with structural features suitable for targeting CK1ε in lymphoma cells[4].
In Vivo	In a subcutaneous xenograft model of T-cell acute lymphoblastic leukemia (T-ALL) in NOD/SCID mice using the MOLT-4 cell line, Umbralisib sulfate (150 mg/kg, daily p.o.) significantly shrinks the tumors by day 25[4].
References	[1]. Maharaj K, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul 14;4(13):3072-3084. [2]. Burris HA 3rd, et al. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486-496. [3]. Swaroop Vakkalankaa, et al. Inhibition of PI3Kδ kinase by a selective, small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth. [4]. Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99.

Melting Point	125 - 127 °C
Molecular Formula	C₃₁H₂₆F₃N₅O₇S
Molecular Weight	669.62800
Exact Mass	669.15100
PSA	192.04000
LogP	7.67190

1532533-75-7	1532533-67-7
1532533-72-4	1532533-69-9
1532533-78-0	894783-71-2
811-92-7	45247-34-5
61-47-2	26182-60-5
1158522-08-7	940364-43-2
2172548-27-3	134104-43-1
2095192-35-9	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4